UK NAO Cancer Drug Fund Probe Curbed By Data Gaps
This article was originally published in Scrip
Executive Summary
England's Cancer Drug Fund (CDF) seems to have contributed to the use of innovative drugs in the UK but its actual impact on patient outcomes is unclear, due to lack of evidence, according to a study by Britain's National Audit Office (NAO).